Over the course of this series, we have followed a single argument through four posts: the pharmacokinetic instability of large infrequent testosterone injections is not an inherent feature of testosterone therapy. It is a feature of that particular delivery format. Change the format, and the instability resolves.
The transdermal spray is the most complete clinical implementation of that resolution currently available for daily self-administration.
What Bioequivalent to Androgel Actually Means
AndroGel — 1% transdermal testosterone gel — was approved by the FDA in 2000 and became the most prescribed testosterone formulation in the world. Two formulations are bioequivalent when their 90% confidence intervals for both Cmax and AUC fall within the 80% to 125% range. A testosterone transdermal spray meeting this standard delivers testosterone to the bloodstream at the same rate and to the same extent as AndroGel — which means it inherits the same 25-year clinical evidence base.
Why Spray Solves What Gel Created
Daily transdermal gel was a genuine pharmacokinetic advance over injection protocols. Spray formulations address the practical compliance issues that limited gel adoption:
Transfer risk: Testosterone gel carries documented transfer risk. The FDA's black-box warning on transdermal gels exists because transfer events involving unintended virilization in children were reported in clinical literature. Spray formulations dry rapidly and leave minimal surface residue, substantially reducing this risk.
Drying and residue: Spray application is faster and cleaner than gel. Metered-dose spray delivers a fixed, consistent amount per actuation, improving dose precision over gel which can vary with application technique.
The Complete Stability Picture
Daily transdermal delivery produces a peak-to-trough free testosterone variation of approximately 2.7 pg/mL. Traditional weekly intramuscular injection produces approximately 26.7 pg/mL — a 10x difference achieved not by using a different drug, but by distributing it differently. Oral testosterone produces wide fluctuations and rapid hepatic clearance. Sublingual testosterone spikes within the first hour and falls below normal range within two hours.
Daily transdermal spray sits at the stable end of this spectrum. The serum profile it produces mirrors what the body does on its own — a near-flat line that stays within the therapeutic range across the full 24-hour period.
The Regulatory and Evidence Picture
Bioequivalence to AndroGel means the transdermal spray is regulated against the same evidence base that established daily transdermal testosterone as safe and effective. That evidence base includes the Testosterone Trials, showing improvements across sexual function, energy, and bone density. And it includes the TRAVERSE trial, which enrolled 5,246 men over a median of 22 months and found no increase in major cardiovascular events with daily transdermal testosterone therapy versus placebo.
What This Series Has Been Building To
The dose problem was never about the drug. Testosterone works. It has worked for decades. The problem was a delivery format — large infrequent bolus injections — that forces patients to experience the therapy at its worst and its best on a seven-day loop, with the worst clustered at exactly the point when they most want the therapy to be working. The transdermal spray does not cure testosterone deficiency. Neither does any TRT formulation. What it does is deliver the therapy the way the physiology expects it: steadily, continuously, and without the cycle.
